JP5652983B2 - 局所適用可能な薬剤学的製剤 - Google Patents
局所適用可能な薬剤学的製剤 Download PDFInfo
- Publication number
- JP5652983B2 JP5652983B2 JP2004506857A JP2004506857A JP5652983B2 JP 5652983 B2 JP5652983 B2 JP 5652983B2 JP 2004506857 A JP2004506857 A JP 2004506857A JP 2004506857 A JP2004506857 A JP 2004506857A JP 5652983 B2 JP5652983 B2 JP 5652983B2
- Authority
- JP
- Japan
- Prior art keywords
- roflumilast
- pharmaceutical formulation
- topical pharmaceutical
- topical
- formulation according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0043—Nose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/12—Crossbows
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/12—Crossbows
- F41B5/123—Compound crossbows
-
- F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
- F41—WEAPONS
- F41B—WEAPONS FOR PROJECTING MISSILES WITHOUT USE OF EXPLOSIVE OR COMBUSTIBLE PROPELLANT CHARGE; WEAPONS NOT OTHERWISE PROVIDED FOR
- F41B5/00—Bows; Crossbows
- F41B5/14—Details of bows; Accessories for arc shooting
- F41B5/1442—Accessories for arc or bow shooting
- F41B5/1469—Bow-string drawing or releasing devices
Description
例1
次のもの550gを含有する:
ポリエチレングリコール400 440.00g
Carbopol 934(R) 8.25g
ロフルミラスト 1.375g
水酸化ナトリウム溶液 十分な量
純水 550.00gまで
製造は約60〜70℃で挙げられた量のポリエチレングリコール中に活性成分を溶解させることにより行う。純水約90gを添加し、かつ均質に混合し、Carbopol 934を高速撹拌機を用いてその中に均質に分散させる。ゆっくりと撹拌しながら、水酸化ナトリウム溶液を、6.5〜7.5のpHに達するまで添加する。残りの水を最終質量まで添加し、均質に混合する。
例2
次のもの550gを含有する:
ロフルミラスト 1.65g
ポリエチレングリコール400 440.00g
ポリエチレングリコール4000 550.0gまで
製造は、2つのポリエチレングリコールを70℃に処理して澄明な融成物を得ることにより行う。活性成分を同様に添加して澄明な溶液を得る。製剤を、ゆっくりと撹拌しながら室温に冷却する。
例3
次のもの550gを含有する:
ロフルミラスト 1.10g
Tego Care 150(R) 27.50g
(Th. Goldschmidt)
ニュートラルオイル(Miglyol 812(R)) 137.50g
ポリエチレングリコール400 275.00g
セトステアリルアルコール 11.00g
純水 550gまで
製造を、ニュートラルオイル、セトステアリルアルコール及びTego Care 150の澄明な溶液を約70℃で製造することにより行う。ロフルミラストが溶解されているポリエチレングリコールを、同様に高速撹拌機を用いて撹拌混入する。70℃に加熱した水を脂質相に添加する。Turraxを均質化のために使用する。ついで製剤を冷たくなる(室温)まで撹拌する。
例4
次のもの100gを含有する:
ロフルミラスト 0.25g
ニュートラルオイル(Miglyol 812(R)) 16.00g
グリセリンモノステアレート 8.00g
Cremophor A6(R) (BASF) 4.00g
ポリエチレングリコール400 62.50g
純水 100.00gまで
製造を、全ての成分(水を除く)を一緒に約70〜80℃に加熱して澄明な溶液を得ることにより行う。ついで水を、撹拌しながら添加し、このようにして製造した製剤を、撹拌しながら室温に冷却する。
例5
次のもの100gを含有する:
ロフルミラスト 0.25g
流動パラフィン 15.00g
羊毛脂 5.00g
白色ワセリン 100gまで
製造を、流動パラフィン、羊毛脂及び白色ワセリンの澄明な融成物を約80℃で製造することにより行う。超微粉砕された活性成分を添加し、製剤を、室温に冷却されるまで撹拌する。
例6
ロフルミラスト 0.10g
流動パラフィン 10.00g
羊毛脂 5.00g
白色ワセリン 100gまで
製造を例5に類似して行う。
例7
ロフルミラスト 0.10g
ニュートラルオイル(Miglyol 812(R)) 16.00g
グリセリンモノステアレート 8.00g
Cremophor A6(R)(BASF) 2.00g
ポリエチレングリコール400 62.50g
純水 100.00gまで
製造を例4に類似して行う。
例8
ロフルミラスト 0.10g
ニュートラルオイル (Miglyol 812(R)) 16.00g
グリセリンモノステアレート 8.00g
Cremophor A6(R) (BASF) 4.00g
ポリエチレングリコール400 62.50g
純水 100.00gまで
製造を例4に類似して行う。
例9
眼軟膏剤の組成(1 000gについての量)
ロフルミラスト 1g
セチルアルコール 4g
高粘度パラフィン 200g
白色ワセリン 795g
製造:セチルアルコール、高粘度パラフィン及び白色ワセリンの澄明な融成物を約70℃で製造する。超微粉砕されたロフルミラスト(10μm未満の粒子90%)を撹拌混入し、均質な分散液をUltra-Turraxを用いて製造する。懸濁液を、撹拌しながら室温に冷却し、適しているチューブに充填するのに使用する。
例10
乳剤の形の点眼溶液の組成(1 000mlについての量)
ロフルミラスト 1.5g
中鎖トリグリセリド 100.0g
レシチン 12.0g
グリセリン 25.0g
チオメルサール 0.1g
純水 1 000mlまで
製造:最初にロフルミラスト及びついでレシチンを、中鎖トリグリセリド及びグリセリン中に30℃〜40℃で溶解させる。激しく撹拌しながら純水を添加し、ついで分散相の液滴サイズが500nm未満になるまで均質化する。チオメルサールを、撹拌することにより溶解させる。乳濁液を0.45μmフィルターでろ過し、適している容器中に分配する。
例11
鼻軟膏剤の組成(1 000gについての量)
ロフルミラスト 1g
セチルアルコール 4g
羊毛脂 50g
高粘度パラフィン 200g
白色ワセリン 745g
製造:セチルアルコール、高粘度パラフィン、羊毛脂及び白色ワセリンの澄明な融成物を約70℃で製造する。超微粉砕されたロフルミラスト(10μm未満の粒子90%)を撹拌混入し、均質な分散液をUltra-Turraxを用いて製造する。懸濁液を、撹拌しながら室温に冷却し、適しているチューブに充填するのに使用する。
局所的薬剤学的製剤の薬物動力学の調査
本発明の局所的薬剤学的製剤の薬物動力学パラメーターと経口形との比較
例A
[14C]ロフルミラストを含有している、例7に相当する製剤及び例8に相当する製剤を、サイズ4cm2でラットの皮膚の毛を剃った領域(5匹の雄のウィスターラット)に適用した。放射能濃度を1h、4h、8h、24h後に血漿中で及び尿(0〜24h)中で測定した(n=5)。用量は1.7mg/kgであった。
結果:
例7の製剤:Cmax:0.214mg当量/l、AUC(0-24h):4.13(mg当量/l×h)
例8の製剤:Cmax:0.214mg当量/l、AUC(0-24h):3.99(mg当量/l×h)
1mg/kgに標準化した結果は次の通りである:
例7の製剤:Cmax:0.126、AUC:2.43
例8の製剤:Cmax:0.126、AUC:2.35
1mg/kgの経口投与後の動力学的パラメーターとの比較:
Cmax:0.225mg当量/l、AUC(0-24h):3.10(mg当量/l×h)
AUC(例7の製剤)とAUC(経口)との比は78%であり、かつAUC(例8の製剤)とAUC(経口)との比は76%である。
例7の製剤:用量の19.4%
例8の製剤:用量の18.0%
経口投与:用量の18.4%
結論:
ラットへの[14C]ロフルミラスト1.7mg/kgの経皮投与後に、全放射能は皮膚を通して十分に輸送され、使用された製剤に関係なく4h後に0.214mg当量/lの最大血漿レベルに達する。経皮投与後の全放射能、AUCs及び尿での排泄に基づいて経口投与後のそれとは取るに足るほど違わない。
例B
[14C]ロフルミラストを含有している例5に相当する製剤を、サイズ4cm2でラットの皮膚の毛を剃った領域(雄のウィスターラット)に適用した。放射能濃度を、1h、4h、8h、24h後に血漿中で及び尿(0〜24h)中で測定した(n=5)。用量は1.77mg/kgであった。
例5の製剤:Cmax:0.331mg当量/l、AUC(0-24h):4.99(mg当量/l×h)
1mg/kgに標準化した結果は次の通りである:
例5の製剤:Cmax:0.187、AUC:2.82
1mg/kgの経口投与後の動力学的パラメーターとの比較:
Cmax:0.225mg当量/l、AUC(0-24h):3.10(mg当量/l×h)
尿での排泄の比較結果:
例5の製剤:用量の22.0%
経口投与:用量の18.4%
結論:
これらのデータは、ロフルミラストが、例7又は8に相当する製剤からよりも、幾分より一層良好に例5の製剤から吸収されることを示している。投与後24h内の尿での排泄は22%であり、これは例7又は8に相当する製剤の皮膚投与後の尿での排泄の範囲内でもある。経口投与との比較は、局所製剤の組成に関係なく、類似のCmax及びAUCs及び類似の尿での排泄が達成されることを示している。
Claims (7)
- 局所投与に適している1つ又はそれ以上の薬剤学的なキャリヤー及び/又は付形剤と共に活性薬剤学的成分を含んでいる、乾癬(尋常性)、有毒性及びアレルギー性の接触湿疹、アトピー性湿疹、脂漏性湿疹、単純苔癬、日焼け、生殖肛門領域におけるそう痒症、円形脱毛症、過形成性瘢痕、円板状エリテマトーデス、毛包性及び拡張性の膿皮症、内因性及び外因性のざ瘡、酒さ性ざ瘡又は他の増殖性、炎症性及びアレルギー性の皮膚障害を処置するための皮膚投与用の局所的薬剤学的製剤において、
活性薬剤学的成分が、ロフルミラスト、ロフルミラストの塩、ロフルミラストのピリジン残基のN−オキシド又はその塩からなっている群から選択される化合物であり、かつキャリヤー及び/又は付形剤の1つが固体又は液体のパラフィン及びポリアルコールの群から選択されることを特徴とする、皮膚投与用の局所的薬剤学的製剤。 - ポリアルコールがグリセリン、ソルビトール、プロピレングリコール及び/又はポリエチレングリコールからなる群から選択される、請求項1記載の局所的薬剤学的製剤。
- キャリヤー及び/又は付形剤の1つがポリエチレングリコールである、請求項1記載の局所的薬剤学的製剤。
- 薬剤学的製剤が1用量単位当たりロフルミラスト、ロフルミラストの塩、ロフルミラストのピリジン残基のN−オキシド又はその塩0.005mg〜5mgを含有する、請求項1記載の局所的薬剤学的製剤。
- 軟膏剤(例えば溶液性軟膏、懸濁性軟膏)、クリーム、ゲル又は泥膏の群から選択される半固体の剤形である、請求項1記載の局所的薬剤学的製剤。
- 経皮吸収治療システム(TTS)である、請求項1記載の局所的薬剤学的製剤。
Applications Claiming Priority (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02011830.3 | 2002-05-28 | ||
DE10223828 | 2002-05-28 | ||
EP02011830 | 2002-05-28 | ||
DE10223828.6 | 2002-05-28 | ||
DE10311613.3 | 2003-03-14 | ||
DE10311613 | 2003-03-14 | ||
PCT/EP2003/005524 WO2003099334A1 (en) | 2002-05-28 | 2003-05-27 | Topically applicable pharmaceutical preparation |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012154020A Division JP5683538B2 (ja) | 2002-05-28 | 2012-07-09 | 局所適用可能な薬剤学的製剤 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2005529930A JP2005529930A (ja) | 2005-10-06 |
JP5652983B2 true JP5652983B2 (ja) | 2015-01-14 |
Family
ID=29587313
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004506802A Pending JP2005529928A (ja) | 2002-05-28 | 2003-05-27 | 眼の病気を治療するためのロフルミラストの眼科的使用 |
JP2004506857A Expired - Lifetime JP5652983B2 (ja) | 2002-05-28 | 2003-05-27 | 局所適用可能な薬剤学的製剤 |
JP2012154020A Expired - Lifetime JP5683538B2 (ja) | 2002-05-28 | 2012-07-09 | 局所適用可能な薬剤学的製剤 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2004506802A Pending JP2005529928A (ja) | 2002-05-28 | 2003-05-27 | 眼の病気を治療するためのロフルミラストの眼科的使用 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012154020A Expired - Lifetime JP5683538B2 (ja) | 2002-05-28 | 2012-07-09 | 局所適用可能な薬剤学的製剤 |
Country Status (33)
Country | Link |
---|---|
US (7) | US20060084685A1 (ja) |
EP (3) | EP2020243B1 (ja) |
JP (3) | JP2005529928A (ja) |
KR (2) | KR20050014844A (ja) |
CN (3) | CN101491520B (ja) |
AT (2) | ATE485821T1 (ja) |
AU (2) | AU2003240719B2 (ja) |
BR (2) | BR0311339A (ja) |
CA (2) | CA2486910C (ja) |
CY (2) | CY1110312T1 (ja) |
DE (2) | DE60325354D1 (ja) |
DK (3) | DK1511516T3 (ja) |
EA (2) | EA010416B1 (ja) |
ES (3) | ES2354971T3 (ja) |
HK (2) | HK1079437A1 (ja) |
HR (1) | HRP20041211B1 (ja) |
HU (1) | HUE039709T2 (ja) |
IL (3) | IL164935A (ja) |
IS (1) | IS2639B (ja) |
LT (1) | LT2020243T (ja) |
MA (1) | MA27813A1 (ja) |
ME (1) | ME00565A (ja) |
MX (2) | MXPA04011528A (ja) |
NO (2) | NO334882B1 (ja) |
NZ (3) | NZ536920A (ja) |
PL (3) | PL211870B1 (ja) |
PT (3) | PT1511481E (ja) |
RS (1) | RS51104B (ja) |
SI (2) | SI2020243T1 (ja) |
TR (1) | TR201815573T4 (ja) |
UA (2) | UA88523C2 (ja) |
WO (2) | WO2003099278A1 (ja) |
ZA (2) | ZA200408649B (ja) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6872382B1 (en) | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
JP2005529928A (ja) * | 2002-05-28 | 2005-10-06 | アルタナ ファルマ アクチエンゲゼルシャフト | 眼の病気を治療するためのロフルミラストの眼科的使用 |
KR20050057175A (ko) | 2002-09-20 | 2005-06-16 | 알콘, 인코퍼레이티드 | 안구건조증 치료용 사이토카인 합성 저해제의 용도 |
FR2851247B1 (fr) | 2003-02-19 | 2007-06-29 | Exonhit Therapeutics Sa | Methodes et compositions pour le traitement de pathologies degeneratives oculaires |
RS52908B (en) | 2003-03-10 | 2014-02-28 | Takeda Gmbh | NEW PROCEDURE FOR OBTAINING ROFLUMILAST |
CA2552524A1 (en) * | 2004-01-10 | 2005-07-28 | Biolipid, Inc. | Lipid compositions and methods of use |
DE102004046235A1 (de) * | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
DE102004046236A1 (de) * | 2004-09-22 | 2006-03-30 | Altana Pharma Ag | Arzneimittelzubereitung |
JP5091106B2 (ja) * | 2005-03-08 | 2012-12-05 | ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング | 真性糖尿病の治療のためのロフルミラスト |
WO2006097456A1 (en) * | 2005-03-16 | 2006-09-21 | Nycomed Gmbh | Taste masked dosage form containing roflumilast |
WO2006132342A1 (ja) * | 2005-06-09 | 2006-12-14 | Santen Pharmaceutical Co., Ltd. | ロフルミラスト点眼液 |
AU2007218725B2 (en) | 2006-02-21 | 2011-12-01 | Eisai R & D Management Co., Ltd. | 4-(3-benzoylaminophenyl)-6,7-dimethoxy-2- methylaminoquinazoline derivative |
CA2678477A1 (en) | 2007-02-16 | 2008-08-21 | Eisai R&D Management Co., Ltd. | Crystal, amorphous form and salt of methyl n-[3-(6,7-dimethoxy-2-methylaminoquinazolin-4-yl)phenyl]terephthalamic acid |
KR20100042245A (ko) | 2007-08-17 | 2010-04-23 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 퀴나졸린 유도체의 제조 방법 |
EP2202229B1 (en) | 2007-08-17 | 2012-03-14 | Eisai R&D Management Co., Ltd. | Novel preparation for external use |
US20120270954A1 (en) | 2009-10-30 | 2012-10-25 | Yuanlong Pan | Methods for maintaining eye health and ameliorating opthalmic maladies in canines |
ES2377785B2 (es) | 2010-09-08 | 2012-09-26 | Universidad Miguel Hernández De Elche | Composición farmacéutica para el tratamiento del ojo seco. |
ES2408132B1 (es) * | 2010-09-08 | 2014-04-04 | Universidad Miguel Hernández De Elche | Composición farmacéutica para el tratamiento de la epífora. |
ES2868231T3 (es) * | 2011-03-07 | 2021-10-21 | Amgen Europe Gmbh | Métodos de tratamiento de enfermedades usando compuestos de isoindolina |
CN102793684B (zh) * | 2011-05-26 | 2016-02-17 | 杭州赛利药物研究所有限公司 | 罗氟司特液体制剂及其制备方法 |
PE20141031A1 (es) * | 2011-06-28 | 2014-08-21 | Bayer Healthcare Llc | Composicion farmaceutica oftalmologica topica que contiene regorafenib |
WO2013155123A1 (en) * | 2012-04-10 | 2013-10-17 | Georgia State University Research Foundation, Inc. | Compositions and methods for treating otitis media and other conditions with inhibitors of cyld |
WO2014012954A1 (en) | 2012-07-18 | 2014-01-23 | Takeda Gmbh | Treatment of partly controlled or uncontrolled severe asthma |
CN103570610B (zh) * | 2012-07-18 | 2017-08-11 | 重庆华邦制药有限公司 | 一种罗氟司特微粒的制备方法 |
CA2889905A1 (en) | 2012-11-08 | 2014-05-15 | Rhizen Pharmaceuticals Sa | Pharmaceutical compositions containing a pde4 inhibitor and a pi3 delta or dual pi3 delta-gamma kinase inhibitor |
AU2014307803A1 (en) | 2013-08-16 | 2016-03-10 | Universiteit Maastricht | Treatment of cognitive impairment with PDE4 inhibitor |
CN105434328A (zh) * | 2014-09-01 | 2016-03-30 | 天津药物研究院有限公司 | 一种含罗氟司特固体分散体的固体制剂及其制备方法 |
WO2016063906A1 (ja) * | 2014-10-24 | 2016-04-28 | 久光製薬株式会社 | プロドラッグ |
CN104997959A (zh) * | 2015-08-21 | 2015-10-28 | 蔡宇平 | 一种用于治疗睑板腺囊肿的中药 |
CN106148528B (zh) * | 2016-07-11 | 2019-10-01 | 赵晨 | 一种遗传性Usher综合征的致病突变及其检测试剂 |
US9895359B1 (en) | 2017-06-07 | 2018-02-20 | Arcutis, Inc. | Inhibition of crystal growth of roflumilast |
US11129818B2 (en) | 2017-06-07 | 2021-09-28 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having improved delivery and plasma half life |
US11534493B2 (en) * | 2017-09-22 | 2022-12-27 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast in aqueous blends of water-miscible, pharmaceutically acceptable solvents |
CN108283620A (zh) * | 2018-03-13 | 2018-07-17 | 兆科药业(广州)有限公司 | 一种磷酸二酯酶-4抑制剂的局部药物组合物及其制备方法 |
US20190365642A1 (en) * | 2018-06-04 | 2019-12-05 | Arcutis, Inc. | Method and Formulation for Improving Roflumilast Skin Penetration Lag Time |
KR102117525B1 (ko) * | 2018-07-09 | 2020-06-01 | 건양대학교 산학협력단 | Pde4b 저해제를 유효성분으로 함유하는 만성 부비동염에서의 비용종 발생의 예방 및 치료용 약학 조성물 |
US20200155524A1 (en) * | 2018-11-16 | 2020-05-21 | Arcutis, Inc. | Method for reducing side effects from administration of phosphodiesterase-4 inhibitors |
AU2021214399A1 (en) | 2020-01-31 | 2022-08-25 | Arcutis Biotherapeutics, Inc. | Topical roflumilast formulation having improved delivery and plasma half-life |
KR20220074935A (ko) * | 2020-05-07 | 2022-06-03 | 아큐티스 바이오테라퓨틱스, 인크. | 높은 크라프트 온도 음이온성 계면활성제를 이용한 피부병의 치료 |
WO2022169615A1 (en) | 2021-02-05 | 2022-08-11 | Arcutis Biotherapeutics, Inc. | Roflumilast formulations with an improved pharmacokinetic profile |
CN116867480A (zh) * | 2021-02-10 | 2023-10-10 | 洛利克斯治疗有限公司 | 眼部递送罗氟司特的方法 |
WO2022173923A1 (en) * | 2021-02-10 | 2022-08-18 | Iolyx Therapeutics, Inc. | Methods for ophthalmic delivery of roflumilast |
KR20240039092A (ko) * | 2021-06-01 | 2024-03-26 | 아이디어 바이오, 엘엘씨 | 안구 약물을 위한 연장 방출 약물 전달 시스템 및 사용 방법 |
WO2023049809A1 (en) * | 2021-09-22 | 2023-03-30 | Iolyx Therapeutics, Inc. | Methods of treating ocular inflammatory diseases |
US20240108609A1 (en) | 2022-09-15 | 2024-04-04 | Arcutis Biotherapeutics, Inc. | Pharmaceutical compositions of roflumilast and solvents capable of dissolving high amounts of the drug |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4753945A (en) * | 1986-02-19 | 1988-06-28 | Eye Research Institute Of Retina Foundation | Stimulation of tear secretion with phosphodiesterase inhibitors |
US5011843A (en) * | 1988-05-31 | 1991-04-30 | Iolab Corporation | Treatment of glaucoma using phosphodiesterase inhibitors |
US5891904A (en) * | 1992-09-14 | 1999-04-06 | Wolf-Georg Forssmann | Use of inhibitors of phosphodiesterase IV |
CA2165192C (en) * | 1993-07-02 | 2001-04-24 | Hermann Amschler | Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors |
EP0719561A4 (en) * | 1993-08-10 | 1997-07-30 | Fujisawa Pharmaceutical Co | Percutaneous absorbent preparation |
ZA954599B (en) * | 1994-06-07 | 1996-01-26 | Allergan Inc | Stable gel formulation for topical treatment of skin conditions |
CA2345362A1 (en) * | 1998-09-29 | 2000-04-06 | Fujisawa Pharmaceutical Co., Ltd. | Novel salts of pyridopyrazine compound and crystals thereof |
US6395746B1 (en) * | 1998-09-30 | 2002-05-28 | Alcon Manufacturing, Ltd. | Methods of treating ophthalmic, otic and nasal infections and attendant inflammation |
US20020006418A1 (en) * | 1998-10-13 | 2002-01-17 | John Kung | Composition to enhance permeation of topical skin agents |
WO2000053182A2 (en) | 1999-03-10 | 2000-09-14 | Byk Gulden Lomberg Chemische Fabrik Gmbh | 3-cyclopropylmethoxy-4-difluoromethoxy-n-(3,5-dichloropyrid-4-yl)benzamide in the treatment of multiple sclerosis |
US6174878B1 (en) * | 1999-08-31 | 2001-01-16 | Alcon Laboratories, Inc. | Topical use of kappa opioid agonists to treat otic pain |
TR200201150T2 (tr) * | 1999-10-29 | 2002-09-23 | Smithkline Beecham Corporation | Bir fosfodiesteraz 4 inhibitörünün uygulanmasına dair metod. |
JP2003522165A (ja) * | 2000-01-31 | 2003-07-22 | ファイザー・プロダクツ・インク | Pde4アイソザイムの阻害剤として有用なピリミジンカルボキサミド |
JP2004502643A (ja) * | 2000-02-16 | 2004-01-29 | ユニバーシティ・オブ・ネブラスカ・メディカル・センター | 線維症性疾患の治療法および治療用組成物 |
AU6196201A (en) * | 2000-05-25 | 2001-12-03 | Merck Frosst Canada Inc | Fluoroalkoxy-substituted benzamide dichloropyridinyl n-oxide pde4 inhibitor |
AU2002227123A1 (en) * | 2000-11-07 | 2002-05-21 | Merck And Co., Inc. | Method of treatment with a combination of a pde4 inhibitor and a leukotriene antagonist |
UA77656C2 (en) * | 2001-04-07 | 2007-01-15 | Glaxo Group Ltd | S-fluoromethyl ester of 6-alpha, 9-alpha-difluoro-17-alpha-[(2-furanylcarbonyl)oxy]-11-beta-hydroxy-16- alpha-methyl-3-oxoandrosta-1,4-dien-17-beta-carbothioacid as anti-inflammatory agent |
US6872382B1 (en) * | 2001-05-21 | 2005-03-29 | Alcon, Inc. | Use of selective PDE IV inhibitors to treat dry eye disorders |
US20030092706A1 (en) * | 2001-11-09 | 2003-05-15 | Johannes Barsig | Combination |
JP2005529928A (ja) * | 2002-05-28 | 2005-10-06 | アルタナ ファルマ アクチエンゲゼルシャフト | 眼の病気を治療するためのロフルミラストの眼科的使用 |
-
2003
- 2003-05-27 JP JP2004506802A patent/JP2005529928A/ja active Pending
- 2003-05-27 NZ NZ536920A patent/NZ536920A/en not_active IP Right Cessation
- 2003-05-27 ES ES03730122T patent/ES2354971T3/es not_active Expired - Lifetime
- 2003-05-27 PL PL372082A patent/PL211870B1/pl unknown
- 2003-05-27 DK DK03755048T patent/DK1511516T3/da active
- 2003-05-27 AU AU2003240719A patent/AU2003240719B2/en not_active Ceased
- 2003-05-27 EP EP08166780.0A patent/EP2020243B1/en not_active Expired - Lifetime
- 2003-05-27 PT PT03730122T patent/PT1511481E/pt unknown
- 2003-05-27 MX MXPA04011528A patent/MXPA04011528A/es active IP Right Grant
- 2003-05-27 HU HUE08166780A patent/HUE039709T2/hu unknown
- 2003-05-27 SI SI200332580T patent/SI2020243T1/sl unknown
- 2003-05-27 AT AT03730122T patent/ATE485821T1/de active
- 2003-05-27 MX MXPA04011612A patent/MXPA04011612A/es active IP Right Grant
- 2003-05-27 PT PT08166780T patent/PT2020243T/pt unknown
- 2003-05-27 NZ NZ537308A patent/NZ537308A/en not_active IP Right Cessation
- 2003-05-27 DE DE60325354T patent/DE60325354D1/de not_active Expired - Lifetime
- 2003-05-27 ES ES08166780.0T patent/ES2693094T3/es not_active Expired - Lifetime
- 2003-05-27 PL PL372095A patent/PL212134B1/pl unknown
- 2003-05-27 UA UAA200712909A patent/UA88523C2/ru unknown
- 2003-05-27 EA EA200401517A patent/EA010416B1/ru not_active IP Right Cessation
- 2003-05-27 UA UA20041210683A patent/UA81910C2/uk unknown
- 2003-05-27 CN CN2009100043805A patent/CN101491520B/zh not_active Expired - Fee Related
- 2003-05-27 AT AT03755048T patent/ATE417628T1/de active
- 2003-05-27 DK DK03730122.3T patent/DK1511481T3/da active
- 2003-05-27 US US10/515,896 patent/US20060084685A1/en not_active Abandoned
- 2003-05-27 BR BR0311339-6A patent/BR0311339A/pt not_active Application Discontinuation
- 2003-05-27 ES ES03755048T patent/ES2319517T3/es not_active Expired - Lifetime
- 2003-05-27 KR KR10-2004-7019272A patent/KR20050014844A/ko not_active Application Discontinuation
- 2003-05-27 DK DK08166780.0T patent/DK2020243T3/en active
- 2003-05-27 DE DE60334692T patent/DE60334692D1/de not_active Expired - Lifetime
- 2003-05-27 CN CN038124068A patent/CN1655823B/zh not_active Expired - Fee Related
- 2003-05-27 BR BR0311337-0A patent/BR0311337A/pt not_active Application Discontinuation
- 2003-05-27 KR KR1020117025130A patent/KR101307093B1/ko not_active IP Right Cessation
- 2003-05-27 NZ NZ553731A patent/NZ553731A/en not_active IP Right Cessation
- 2003-05-27 RS YUP-1014/04A patent/RS51104B/sr unknown
- 2003-05-27 WO PCT/EP2003/005536 patent/WO2003099278A1/en active Application Filing
- 2003-05-27 US US10/515,698 patent/US20060084684A1/en not_active Abandoned
- 2003-05-27 CA CA2486910A patent/CA2486910C/en not_active Expired - Fee Related
- 2003-05-27 EA EA200702588A patent/EA020569B1/ru not_active IP Right Cessation
- 2003-05-27 CA CA2486917A patent/CA2486917C/en not_active Expired - Fee Related
- 2003-05-27 WO PCT/EP2003/005524 patent/WO2003099334A1/en active Application Filing
- 2003-05-27 LT LTEP08166780.0T patent/LT2020243T/lt unknown
- 2003-05-27 AU AU2003232828A patent/AU2003232828B2/en not_active Ceased
- 2003-05-27 CN CNB038120941A patent/CN100490804C/zh not_active Expired - Fee Related
- 2003-05-27 JP JP2004506857A patent/JP5652983B2/ja not_active Expired - Lifetime
- 2003-05-27 ME MEP-854/08A patent/ME00565A/xx unknown
- 2003-05-27 TR TR2018/15573T patent/TR201815573T4/tr unknown
- 2003-05-27 PT PT03755048T patent/PT1511516E/pt unknown
- 2003-05-27 SI SI200331532T patent/SI1511516T1/sl unknown
- 2003-05-27 PL PL397021A patent/PL397021A1/pl unknown
- 2003-05-27 EP EP03755048A patent/EP1511516B1/en not_active Expired - Lifetime
- 2003-05-27 EP EP03730122A patent/EP1511481B1/en not_active Expired - Lifetime
-
2004
- 2004-10-21 MA MA27912A patent/MA27813A1/fr unknown
- 2004-10-26 ZA ZA200408649A patent/ZA200408649B/xx unknown
- 2004-10-31 IL IL164935A patent/IL164935A/en not_active IP Right Cessation
- 2004-11-07 IL IL165065A patent/IL165065A/en active IP Right Grant
- 2004-11-26 ZA ZA200409584A patent/ZA200409584B/xx unknown
- 2004-12-16 NO NO20045506A patent/NO334882B1/no not_active IP Right Cessation
- 2004-12-23 IS IS7612A patent/IS2639B/is unknown
- 2004-12-27 HR HRP20041211AA patent/HRP20041211B1/hr not_active IP Right Cessation
- 2004-12-27 NO NO20045656A patent/NO334916B1/no not_active IP Right Cessation
-
2005
- 2005-12-14 HK HK05111481.8A patent/HK1079437A1/xx not_active IP Right Cessation
- 2005-12-16 HK HK05111628.2A patent/HK1079445A1/xx not_active IP Right Cessation
-
2008
- 2008-04-29 US US12/149,250 patent/US20080280958A1/en not_active Abandoned
-
2009
- 2009-03-10 CY CY20091100273T patent/CY1110312T1/el unknown
-
2010
- 2010-11-30 IL IL209657A patent/IL209657A0/en unknown
-
2011
- 2011-08-26 US US13/219,056 patent/US20110313005A1/en not_active Abandoned
-
2012
- 2012-07-09 JP JP2012154020A patent/JP5683538B2/ja not_active Expired - Lifetime
-
2013
- 2013-11-08 US US14/075,035 patent/US20140303215A1/en not_active Abandoned
-
2018
- 2018-10-03 US US16/150,759 patent/US20190029956A1/en not_active Abandoned
- 2018-10-24 CY CY181101093T patent/CY1121133T1/el unknown
-
2020
- 2020-06-03 US US16/891,823 patent/US20210116207A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5683538B2 (ja) | 局所適用可能な薬剤学的製剤 | |
WO2010041684A1 (ja) | タクロリムス外用剤 | |
WO2005113002A1 (ja) | ムスカリン受容体作動薬を含有する眼科用経皮吸収型製剤 | |
JPH1129483A (ja) | ジフルプレドナート含有組成物 | |
CA2463282A1 (en) | Therapeutical agent for pruritus | |
EP1297849B1 (en) | Remedial agent for optic nerve diseases | |
WO2005007161A1 (ja) | ピペリジン誘導体を有効成分とする掻痒治療剤 | |
JPH04327533A (ja) | 抗アレルギー用粘膜局所投与剤 | |
WO2006062069A1 (ja) | p38MAPキナーゼ阻害剤を有効成分とする掻痒治療剤 | |
WO2005053672A1 (ja) | シロミラストまたはその塩を有効成分とする掻痒治療剤 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20060329 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090819 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091019 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091026 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100217 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20100401 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20100617 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100624 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20101228 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20110713 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20111003 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20111011 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120113 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20120307 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140508 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140513 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140821 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141118 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5652983 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313111 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
EXPY | Cancellation because of completion of term |